dc.contributor.author |
Emilsson, Valur |
dc.contributor.author |
Guðmundsson, Elías F. |
dc.contributor.author |
Aspelund, Thor |
dc.contributor.author |
Jónsson, Brynjólfur G. |
dc.contributor.author |
Guðjónsson, Alexander |
dc.contributor.author |
Launer, Lenore J. |
dc.contributor.author |
Lamb, John R. |
dc.contributor.author |
Guðmundsdóttir, Valborg |
dc.contributor.author |
Jennings, Lori L. |
dc.contributor.author |
Guðnason, Vilmundur G. |
dc.date.accessioned |
2022-02-17T01:01:17Z |
dc.date.available |
2022-02-17T01:01:17Z |
dc.date.issued |
2020-12-16 |
dc.identifier.citation |
Emilsson , V , Guðmundsson , E F , Aspelund , T , Jónsson , B G , Guðjónsson , A , Launer , L J , Lamb , J R , Guðmundsdóttir , V , Jennings , L L & Guðnason , V G 2020 , ' Serum levels of ACE2 are higher in patients with obesity and diabetes ' , Obesity Science and Practice , vol. 7 , no. 2 , pp. 239-243 . https://doi.org/10.1002/osp4.472 |
dc.identifier.issn |
2055-2238 |
dc.identifier.other |
38445845 |
dc.identifier.other |
5efa5676-d310-457d-9de6-2163b8acd848 |
dc.identifier.other |
85097595258 |
dc.identifier.other |
33841894 |
dc.identifier.other |
unpaywall: 10.1002/osp4.472 |
dc.identifier.uri |
https://hdl.handle.net/20.500.11815/2896 |
dc.description |
© 2020 The Authors. Obesity Science & Practice published by World Obesity and The Obesity Society and John Wiley & Sons Ltd. |
dc.description.abstract |
Objective: As severity of outcome in COVID-19 is disproportionately higher among individuals with obesity, smokers, patients with hypertension, kidney disease, chronic pulmonary disease, coronary heart disease (CHD), and/or type 2 diabetes (T2D), serum levels of ACE2, the cellular entry point for the coronavirus SARS-CoV-2, were examined in these high-risk groups. Methods: Associations of ACE2 levels to smokers and patients with hypertension, T2D, obesity, CHD, or COPD were investigated in a single center population-based study of 5457 Icelanders from the Age, Gene/Environment Susceptibility Reykjavík Study (AGES-RS) of the elderly (mean age 75 ± 6 years), using multiple linear regression analysis. Results: Serum levels of ACE2 were higher in smokers and individuals with T2D and/or obesity while they were unaffected in the other patient groups. Conclusion: ACE2 levels are higher in some patient groups with comorbidities linked to COVID-19 including obesity and T2D and as such may have an emerging role as a circulating biomarker for severity of outcome in the disease. |
dc.format.extent |
5 |
dc.format.extent |
312820 |
dc.format.extent |
239-243 |
dc.language.iso |
en |
dc.relation.ispartofseries |
Obesity Science and Practice; 7(2) |
dc.rights |
info:eu-repo/semantics/openAccess |
dc.subject |
Blóðvatn |
dc.subject |
Offita |
dc.subject |
Sykursýki |
dc.subject |
COVID-19 |
dc.subject |
Endocrinology, Diabetes and Metabolism |
dc.subject |
Nutrition and Dietetics |
dc.title |
Serum levels of ACE2 are higher in patients with obesity and diabetes |
dc.type |
/dk/atira/pure/researchoutput/researchoutputtypes/contributiontojournal/article |
dc.description.version |
Peer reviewed |
dc.identifier.doi |
10.1002/osp4.472 |
dc.relation.url |
http://www.scopus.com/inward/record.url?scp=85097595258&partnerID=8YFLogxK |
dc.contributor.department |
Faculty of Medicine |